Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia.
Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.
The ketogenic diet as a treatment paradigm for diverse neurological disorders.
Association between Change in Normal Appearing White Matter Metabolites and Intrathecal Inflammation in Natalizumab-Treated Multiple Sclerosis.
Eicosapentaenoic acid (EPA) induces peroxisome proliferator-activated receptors and ameliorates experimental autoimmune encephalomyelitis.
Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta.
The influence of HLA-DRB1*15 on motor cortical pathology in multiple sclerosis.
The NOX1/4 Inhibitor GKT136901 as Selective and Direct Scavenger of Peroxynitrite.
Low-contrast visual tests reveal better alemtuzumab efficacy
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
Synthon obtains approval for glatiramer acetate 20 mg/mL in Europe
Evaluation of sexual function in women at two stages of multiple sclerosis.
Cancer risk in multiple sclerosis: findings from British Columbia, Canada.
The environment and disease: association or causation?
"Tell me what you want, what you really really want….": asking people with multiple sclerosis about enhancing their participation in physical activity.
An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy.
Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis.
Validity and Reliability of a Persian Translation of the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS).
Active Biotech announce that European Medicines Agency accepts start of scientific review of the marketing authorization application for laquinimod in relapsing-remitting multiple sclerosis
Society for Neuroscience Annual Meeting
Rituximab induces clonal expansion of IgG memory B-cells in patients with inflammatory central nervous system demyelination.
The effect of cannabinoids on the stretch reflex in multiple sclerosis spasticity.
Review of subcutaneous interferon β-1a, delivered via the electronic self-injection device RebiSmart™, for the treatment of multiple sclerosis.
The anti-VLA-4 antibody natalizumab induces erythroblastaemia in the majority of the treated patients with multiple sclerosis.

Pages